Interleukin Receptor Signaling: Mechanistic Analysis of the JAK-STAT and NF-κB Axes with an Overview of Assays, Experimental Models, and Translational Boundaries
Interleukin Receptor Signaling: Mechanistic Analysis of the JAK-STAT and NF-κB Axes with an Overview of Assays, Experimental Models, and Translational Boundaries
Interleukins constitute a key group of cytokines produced by immune cells as well as multiple tissue-resident cell types. Their biological effects depend on the assembly of specific receptor complexes and the magnitude of downstream signal transduction, which in turn shapes immune-cell differentiation, expansion, migration, and effector programs through core pathways such as JAK-STAT and NF-κB, while also contributing to the initiation and resolution of inflammation, barrier homeostasis, tissue repair, hematopoietic regulation, and tumor immunity. Driven by the combined influence of receptor-expression landscapes, microenvironmental cues, and negative-feedback control, the interleukin network exhibits pronounced context dependence and redundant compensatory behavior, and readouts from a single cytokine often simultaneously reflect upstream stimuli, receptor availability, and feedback from parallel pathways.
Keywords: interleukins; cytokine network; receptor complex; JAK-STAT; NF-κB; inflammation; immune differentiation; biomarkers; targeted therapy
I. Concepts, Nomenclature, and Classification Framework of Interleukins
1.1 Concepts and boundaries
(1) Concept definition
Interleukins were initially used to describe soluble factors mediating communication among leukocytes. In the context of modern immunology, interleukins broadly refer to a group of cytokine molecules that trigger signal transduction through specific receptors and exert regulatory effects on the immune system and tissue homeostasis.
(2) Nomenclature characteristics
IL numbering mostly originates from the order of discovery and historical development. The numbering is not equivalent to structural families or shared receptor relationships; functional inference needs to be combined with receptor composition, downstream pathways, and cellular sources.
(3) Network association
Together with chemokines, interferons, and the tumor necrosis factor-related family, interleukins form a cytokine network. Actual biological effects are often determined by multiple factors jointly, and interpretation of the effects of a single IL should avoid being detached from the network context.
1.2 Classification from the perspectives of structure and receptor families
(1) IL-1 family
Typical members include IL-1α, IL-1β, IL-18, and IL-33, and are mostly associated with inflammation initiation, danger-signal integration, and tissue-injury responses.
(2) ILs related to the class I cytokine receptor family
Most transmit signals through the JAK-STAT axis; typical examples include IL-2, IL-4, IL-6, IL-7, IL-9, and members related to the IL-12 family.
(3) IL-17 family-related system
The IL-17 receptor system has distinct features and is often associated with neutrophil recruitment, amplification of barrier-tissue inflammation, and maintenance of chronic inflammation.
(4) IL-10 family-related system
Characterized mainly by immunosuppression and limitation of inflammation. Typical members include IL-10 and also include several members related to mucosal immunity and barrier homeostasis.
1.3 Common organizational approaches for functional lineages
(1) Pro-inflammatory and inflammation-amplification axis
Represented by IL-1, IL-6, and IL-17, often driving amplification of acute inflammation, tissue responses, and changes in systemic inflammatory indicators.
(2) Immune differentiation and effector-program shaping axis
Represented by IL-2, IL-4, IL-7, IL-12, IL-15, IL-21, and IL-23, determining differentiation, expansion, and effector programs of T cells, B cells, and NK cells.
(3) Anti-inflammatory and immune-tolerance axis
Represented by IL-10, limiting pro-inflammatory responses and maintaining tissue homeostasis, but in specific contexts may also coexist with immunosuppressive phenotypes.
II. Receptors and Signal Transduction: The Shared Logic of Interleukin Effects
2.1 Receptor complexes and cell-type specificity
(1) Receptor-expression profiles determine response windows
The same interleukin can exhibit completely different functional effects in different cell types, and a key reason is differences in receptor-chain expression profiles and co-receptor assembly capacity.
(2) Complex assembly determines affinity and dose effects
Most interleukin receptors consist of a specific receptor chain and shared signaling chains. Complex assembly affects ligand affinity, signal strength, and duration, thereby altering the dose–response curve.
(3) Soluble receptors and receptor shedding influence systemic effects
Soluble receptors or receptor-shedding products can alter ligand availability and the range of signal propagation, leading to expansion of local signaling into systemic effects or generating biased signaling patterns.
2.2 Key signaling modules and transcriptional programs
(1) JAK-STAT axis
Plays a core transduction role in multiple IL systems, determining transcriptional outputs for immune differentiation, proliferation, and survival signals.
(2) NF-κB and MAPK axes
Often activated in inflammation initiation and stress responses, driving expression of genes related to pro-inflammatory factors, adhesion molecules, and metabolic adaptation.
(3) Signal strength and duration determine fate divergence
Transient stimulation and sustained exposure can induce different transcriptional programs, causing cells to shift from short-term activation toward exhaustion, tolerance, or tissue-remodeling-related phenotypes.
2.3 Negative feedback and homeostatic control
(1) Endogenous inhibitory factors
Intracellular inhibitory molecules and receptor endocytosis/degradation jointly limit signaling duration and prevent long-term overactivation.
(2) Network redundancy and compensation
After inhibiting an IL axis, upstream stimuli and parallel pathways may be passively enhanced, producing compensatory upregulation of factors; pathway-level validation is required for mechanistic attribution.
(3) Separation of local and systemic readouts
In local microenvironments, concentration gradients and spatial distributions of ILs often do not match peripheral-blood readouts; extrapolation across sample types requires an evidence chain to establish correspondence.
III. Typical Representatives of Interleukin Families: Functional Key Points and Application Notes
3.1 IL-1 family: inflammation initiation and danger-signal integration
(1) IL-1α/IL-1β
① Functional key points: upstream nodes of pro-inflammatory cascades, driving endothelial activation, leukocyte recruitment, and amplification of acute inflammation.
② Application scenarios: mechanistic studies of inflammation initiation, construction of innate-immune activation models, and target validation for inflammatory diseases.
③ Interpretation boundaries: precursor processing, mature-form release, and receptor signaling should be distinguished across three levels, avoiding substituting transcriptional upregulation alone for a conclusion of increased activity.
(2) IL-18 and IL-33
① Functional key points: participate in innate immunity and barrier-tissue immune responses, often associated with tissue stress, cytotoxic responses, and regulation of mucosal immunity.
② Application scenarios: coupling studies of tissue injury and immune activation, and analyses of allergy and mucosal inflammation models.
③ Interpretation boundaries: local source cells and release modes substantially influence effect direction and should be interpreted in combination with tissue localization and receptor-expression profiles.
3.2 IL-2: a core factor for adaptive immune expansion and effector enhancement
(1) Effects on T cells
① Survival and proliferation: IL-2, as a T-cell growth factor, promotes long-term survival of T cells in vitro and drives entry into the cell cycle, markedly improving expansion efficiency.
② Cytotoxicity enhancement: under in vitro conditions, IL-2 in combination with multiple cytokines can promote induction of cytotoxic T cells and enhance their killing function; in vivo it can also enhance the strength of antigen-induced cytotoxic responses.
③ Cytokine-network amplification: IL-2 can induce T cells to secrete cytokines such as IFN-γ, TNF, and CSF, amplifying downstream immune effects.
(2) Effects on NK cells
① Proliferation and maintenance: IL-2 can promote NK-cell proliferation and maintain long-term culture capacity.
② Activity enhancement: it can increase NK-cell cytotoxic activity both in vivo and in vitro, and can show cumulative enhancement that depends on dose and treatment course.
③ Secretion and receptor regulation: IL-2 can promote NK-cell secretion of IFN-γ and increase their responsiveness to IL-2 signaling.
(3) Effects on LAK and TIL-related effector cells
① LAK induction: LAK refers to a highly effective cytotoxic cell population formed by lymphocytes under IL-2 stimulation, and its generation and effector function are highly dependent on IL-2.
② TIL expansion: tumor-infiltrating lymphocytes can be markedly expanded after IL-2 activation in vitro and exhibit strong tumor-killing activity, and under certain conditions their dependence on IL-2 dosage may be relatively reduced.
③ Application boundaries: such strategies require high standards for cell-manufacturing scale, infusion regimens, and systemic toxicity windows; translational design should prioritize safety and exposure control.
(4) Effects on B cells and phagocytes
① B cells: can promote B-cell receptor expression and proliferation and enhance immunoglobulin production capacity.
② Macrophages: can enhance phagocytosis-related functions, thereby supporting innate immune clearance processes.
(5) Additional mechanistic clues for antitumor effects
The antitumor effects of IL-2 mainly follow the line of effector-cell expansion and activation; in some models, phenomena occurring in parallel with changes in NO-related pathways have also been observed and can be proposed as mechanistic components, but should not be generalized as universal conclusions.
3.3 IL-4/IL-5/IL-13: type 2 immunity, allergy, and tissue remodeling
(1) IL-4 and IL-13
① Functional key points: drive type 2 immune bias, participate in mucosal immunity and processes related to antibody class switching, and are associated with tissue remodeling and fibrosis-related phenotypes.
② Application scenarios: mechanistic studies of allergic inflammation, target validation of type 2 immune pathways, and analysis of tissue remodeling models.
③ Interpretation boundaries: acute inflammation stages and chronic remodeling stages should be distinguished in endpoint selection, avoiding using a single time point to cover conclusions across the entire process.
(2) IL-5
① Functional key points: closely associated with eosinophil-related inflammatory phenotypes.
② Application scenarios: construction of eosinophilic inflammation models and evaluation of targeted interventions.
③ Interpretation boundaries: should be combined with tissue infiltrating-cell counts and functional readouts, rather than replacing tissue inflammation severity with peripheral-blood indicators alone.
3.4 IL-6: a convergence node of inflammation, stress, and metabolic regulation
(1) Functional key points
IL-6 can drive acute-phase responses and participate in the formation of systemic inflammatory states, and is also associated with tissue stress, metabolic adaptation, and immune regulation in the tumor microenvironment.
(2) Application scenarios
① Stratification and mechanistic research of inflammatory states: used to characterize inflammation intensity and systemic responses.
② Tumor microenvironment research: used to analyze the coupling between inflammation-associated immunosuppression and tumor progression.
(3) Interpretation boundaries
Confounding variables such as infection, tissue injury, and drug factors need to be incorporated into models; different signaling modes and their contributions to phenotypes should be distinguished, avoiding linear causal expressions based on a single indicator.
3.5 IL-7 and IL-15: lymphocyte homeostasis and maintenance of memory effects
(1) IL-7
① Functional key points: supports T-cell homeostasis and survival signaling, affecting maintenance of the T-cell repertoire and immune reconstitution.
② Application scenarios: immune reconstitution research, T-cell homeostasis models, and support for in vitro culture.
(2) IL-15
① Functional key points: closely associated with maintenance of NK cells and memory-like T cells, supporting durability and functional maintenance of effector cells.
② Application scenarios: design of effector-cell expansion and maintenance protocols and process-optimization research related to cell therapy.
(3) Interpretation boundaries
Under in vitro expansion conditions, phenotype drift that depends on exposure duration readily occurs; combined evaluation using functional endpoints and phenotypic markers is required.
3.6 IL-12/IL-23 and the IL-17 axis: barrier-tissue inflammation and maintenance of chronic inflammation
(1) IL-12
① Functional key points: promotes Th1-like immune programs and shapes cytotoxicity-related responses.
② Application scenarios: mechanistic studies of anti-infection immunity and analyses of tumor-immunity-related pathways.
(2) IL-23
① Functional key points: supports maintenance of the Th17-related axis and is associated with persistence of chronic inflammation.
② Application scenarios: chronic inflammation models and mechanistic studies of barrier-immune imbalance.
(3) IL-17A and related molecules
① Functional key points: promote neutrophil-related inflammatory responses, epithelial barrier responses, and inflammation amplification, and are often linked to maintenance of chronic inflammation.
② Application scenarios: barrier-tissue inflammation models, mechanistic studies of immune diseases, and target validation.
③ Interpretation boundaries: IL-17-related responses are strongly tissue-context dependent and should be interpreted together with microbial stimuli, barrier injury, and tissue-cell responses.
3.7 IL-10: a key factor for limiting inflammation and immune tolerance
(1) Functional key points
IL-10 maintains tissue homeostasis and reduces immune-mediated tissue damage by inhibiting production of pro-inflammatory factors, limiting antigen-presentation-related programs, and reducing inflammation amplification.
(2) Application scenarios
① Mechanistic studies of inflammation resolution stages: analyzing mechanisms that limit inflammation.
② Immune-tolerance-related studies: characterizing immunosuppression and tolerance formation.
(3) Interpretation boundaries
“tissue protection” and “immunosuppression” of IL-10 may coexist; translational statements should clarify disease stage, infection risk, and the tumor-immunity context.
3.8 IL-21 and IL-22: axes related to humoral immunity and barrier repair
(1) IL-21
① Functional key points: participates in germinal-center reactions and shaping of antibody responses, and affects certain T-cell effector programs.
② Application scenarios: mechanistic studies of humoral immunity and analyses of vaccine-related immune responses.
(2) IL-22
① Functional key points: mostly associated with epithelial barrier homeostasis, tissue repair, and mucosal immunity.
② Application scenarios: barrier injury/repair models and studies of mucosal immune microenvironments.
(3) Interpretation boundaries
Such factors are often produced by specific immune-cell subsets and act on tissue cells; tissue receptor expression and epithelial-response endpoints should be evaluated simultaneously.
IV. Assays and Experimental Systems: From Quantification to Functional Validation
4.1 Common detection strategies and applicability
(1) Protein-level quantification
① ELISA and chemiluminescent immunoassays: suitable for single-factor quantification and validation in clinical samples.
② Multiplex assays: suitable for network-level comparisons and exploratory subtyping, but require strict batch control and statistical correction.
(2) Cell-level localization
① Intracellular cytokine staining by flow cytometry: suitable for source-cell localization and assessment of producer proportions.
② Secretion capture and single-cell strategies: suitable for fine localization of secreting cells and analysis of heterogeneity.
(3) Functional assays
① Downstream signaling readouts: such as STAT phosphorylation, used to verify whether signaling truly occurs.
② Functional endpoints: such as proliferation, cytotoxicity, chemotactic migration, phagocytosis, and barrier-repair readouts, used to verify biological effects.
4.2 Sample types and key points in pre-analytical processing
(1) Serum and plasma
Tube type, anticoagulants, and coagulation processes can affect background levels of some factors; collection and centrifugation conditions should be standardized, and repeated freeze–thaw cycles should be avoided.
(2) Tissues and local samples
Tissue homogenates and lavage fluids are closer to local microenvironments but are strongly affected by protease activity and matrix interference; inhibition and processing workflows should be unified and recovery rates recorded.
(3) Cell-culture supernatants
Cell density, medium components, stimulation dose, and time windows markedly affect IL profiles; pilot experiments should be used to determine linear ranges and peak windows.
4.3 Data analysis and boundaries of inference
(1) Multiple comparisons and correlation structure
For multiplex data, multiple-comparison corrections are required and inter-factor correlation structures should be considered, avoiding drawing network conclusions based solely on single-factor significance.
(2) Stratification and confounder control
Age, infection status, medications, comorbidities, and sampling time windows can significantly affect IL profiles; study designs should predefine stratification variables and covariate models.
(3) Causal evidence chains
Observational associations are insufficient to support causal inference; receptor blockade, pathway inhibition, genetic tools, or reverse-validation experiments should be combined to build mechanistic chains.
V. Application Scenarios: Research, Biomarkers, and Translational Interventions
5.1 Basic research applications
(1) Immune differentiation and fate decisions
By setting IL combinations and temporal stimulation sequences, models of T-cell differentiation and effector shaping can be constructed to analyze mechanisms of lineage decisions.
(2) Tissue microenvironment analysis
In contexts such as tumors, mucosa, skin, and neuroimmunity, IL profiles can be used to characterize immune states, communication routes, and key amplification nodes within microenvironments.
(3) Mechanisms of inflammation initiation and resolution
With IL-1 and IL-6 as initiation/amplification axes and IL-10 as a limiting axis, temporal models of inflammation can be constructed to analyze key turning points.
5.2 Biomarkers and disease-subtyping applications
(1) Assessment of inflammatory states
IL profiles can assist in reflecting inflammation intensity and immune bias, but should be interpreted jointly with clinical indicators, cellular composition, and tissue endpoints.
(2) Disease subtypes and prediction of treatment response
There is a research basis linking specific IL combinations to certain disease subtypes, relapse risk, or treatment response, supporting stratification and risk-model construction.
(3) Application boundaries
Interleukins are more suitable as stratification and mechanistic windows; robustness is usually insufficient when used alone as diagnostic bases, requiring multidimensional integration and external validation.
5.3 Targeted therapy and immune-engineering applications
(1) Inhibitory strategies targeting ligands or receptors
Neutralizing ligands or blocking receptors can reduce signaling outputs of specific axes, suitable for inflammatory phenotypes mainly driven by a single pathway.
(2) Downstream pathway inhibition strategies
Inhibiting shared signaling modules can affect multiple IL signals simultaneously and is broad spectrum, but requires higher standards for immunosuppression-risk assessment and infection monitoring.
(3) Support for cell culture and cell therapy
IL-2, IL-7, and IL-15 can be used for in vitro expansion of effector cells and maintenance of function; in process development, dose and exposure time should be constrained jointly by phenotype stability, functional endpoints, and toxicity windows.
(4) Safety and systemic response management
Interleukin-related interventions carry risks of systemic inflammatory responses; a monitoring system for dynamic multi-factor measurements and organ-function assessment should be established, and strategy selection should be based on disease stage and infection risk.
VI. Aladdin-Related Products
Product Category | Product Name | Catalog No. | Grade & Purity | Intended Use |
Recombinant Protein | Recombinant Human IL-2 Protein | Animal Free, Carrier Free, Bioactive, ActiBioPure™, High Performance, ≥95%(SDS-PAGE), See COA, His Tag | In vitro immune cell culture and expansion Functional validation | |
Recombinant Protein | Recombinant Human IL-6 Protein | Animal Free,Carrier Free,Bioactive,ActiBioPure™,High Performance,≥95%(SDS-PAGE),See COA, His Tag | Inflammation and stress axis stimulation Signal and phenotype readout validation | |
Recombinant Protein | Recombinant Human IL-10 Protein | Animal Free, Carrier Free, Bioactive, ActiBioPure™, ≥90%(SDS-PAGE), See COA, His Tag | Anti-inflammatory and immunosuppressive axis research Controls and functional validation | |
Recombinant Protein | Recombinant Human IL-1 alpha/IL-1F1 Protein | ActiBioPure™, Carrier Free, Bioactive, ≥95%(SDS-PAGE) | Inflammation initiation and danger signal model stimulation | |
Recombinant Protein | Recombinant Human IL-1 beta Protein | ActiBioPure™, Bioactive, Animal Free, Carrier Free, Azide Free, High performance, ≥95%(SDS-PAGE), His Tag | Inflammation amplification axis stimulation Innate immune activation models | |
Recombinant Protein | Recombinant Human IL-4 Protein | Animal Free, Carrier Free, Bioactive, ActiBioPure™, High Performance, GMP, ≥95%(SDS-PAGE), See COA, His Tag | Type 2 immune stimulation Differentiation and functional readouts | |
Recombinant Protein | Recombinant Human IL-13 Protein | Bioactive, ActiBioPure™, Animal Free, Carrier Free, High Performance, ≥95%(SDS-PAGE), See COA, His Tag | Type 2 immunity and tissue remodeling pathway stimulation | |
Recombinant Protein | Recombinant Human IL-15 Protein | Animal Free, Carrier Free, Bioactive, ActiBioPure™, High Performance, ≥95%(SDS-PAGE), See COA, His Tag | NK and memory T cell maintenance Support for expansion protocols | |
Recombinant Protein | Recombinant Human IL-17A Protein | Animal Free, Carrier Free, Bioactive, ActiBioPure™, ≥95%(SDS-PAGE), See COA, His Tag | Barrier inflammation and Th17 axis stimulation Chronic inflammation mechanism validation | |
Recombinant Protein | Recombinant Human IL-21 Protein | ActiBioPure™, Bioactive, Animal Free, Carrier Free, Azide Free, High performance, ≥97%(SDS-PAGE&HPLC) | Humoral immunity research Signal pathway validation | |
Recombinant Protein | Recombinant Human IL-22 Protein | ActiBioPure™, Bioactive, Animal Free, Carrier Free, Azide Free, High performance, ≥95%(SDS-PAGE), 1mg/ml, His Tag | Epithelial barrier and repair axis stimulation Functional validation | |
Recombinant Protein | Recombinant Human IL-12 Protein | ActiBioPure™, Bioactive, Animal Free, Carrier Free, Azide Free, High performance, ≥95%(SDS-PAGE) | Th1-like immune programming Anti-infection and tumor immunology mechanism studies | |
Recombinant Protein | Recombinant Human IL-18 Protein | Animal Free,Carrier Free,Bioactive,ActiBioPure™,≥95%(SDS-PAGE),See COA | Innate immunity and inflammation amplification stimulation Network studies | |
Recombinant Protein | Recombinant Human IL-33 Protein | ActiBioPure™, Bioactive, Carrier Free, Azide Free, ≥95%(SDS-PAGE) | Allergy and mucosal immunity axis stimulation Tissue stress models | |
Receptor Protein | Recombinant Human IL-6R Protein | ActiBioPure™, Bioactive, Animal Free, Carrier Free, Azide Free, High performance, ≥90%(SDS-PAGE), His Tag | Receptor binding validation Blocking and neutralization assay setup | |
Receptor Protein | Recombinant Human IL-2 Receptor Alpha Protein | ActiBioPure™, Bioactive, Animal Free, Carrier Free, Azide Free, High performance, ≥97%(SDS-PAGE), His Tag | IL-2 receptor binding validation Assay QC and blocking experiments | |
Receptor Protein | Recombinant Human IL-7R alpha/CD127 Protein | ActiBioPure™, Bioactive, Animal Free, Carrier Free, ≥90%(SDS-PAGE), His Tag | Receptor expression and binding validation Support for flow cytometry and functional studies | |
Receptor Protein | Recombinant Human IL-21R Protein | ActiBioPure™, Bioactive, Animal Free, Carrier Free, Azide Free, High performance, ≥92%(SDS-PAGE), His Tag | IL-21 receptor binding and signaling validation | |
Receptor Protein | Recombinant Human IL-23R Protein | ActiBioPure™, Bioactive, Animal Free, Carrier Free, Azide Free, ≥95%(SDS-PAGE), Fc tag | Receptor-level validation of the IL-23 axis Ligand receptor assay setup | |
Receptor Protein | Recombinant Human IL-10 R alpha Protein | ActiBioPure™, Bioactive, Animal Free, Carrier Free, Azide Free, ≥95%(SDS-PAGE), Fc tag | Receptor-level validation of the IL-10 pathway Blocking assay setup | |
Receptor Protein | Recombinant Human IL-10 R beta Protein | ActiBioPure™, Bioactive, Animal Free, Carrier Free, Azide Free, ≥95%(SDS-PAGE), His Tag | IL-10 family signaling complex studies | |
Receptor Protein | Recombinant Human IL-18 R alpha/IL-1 R5 Protein | ActiBioPure™, Bioactive, Animal Free, Carrier Free, Azide Free, High performance, ≥95%(SDS-PAGE), Fc tag, His Tag | Receptor-level validation of IL-18 Blocking assay setup | |
Receptor Protein | Recombinant Human IL-18 R beta/IL-1 R7 Protein | ActiBioPure™, Bioactive, Animal Free, Carrier Free, Azide Free, High performance, ≥95%(SDS-PAGE), His Tag | IL-18 receptor complex assembly and functional validation | |
Receptor Protein | Recombinant Human IL-1 RAcP/IL-1 R3 Protein | ActiBioPure™, Bioactive, Animal Free, Carrier Free, Azide Free, ≥90%(SDS-PAGE), His Tag | IL-1 family co-receptor studies Signaling system setup | |
Receptor Protein | Recombinant Human IL-13 R alpha 1 Protein | ActiBioPure™, Bioactive, Animal Free, Carrier Free, Azide Free, ≥95%(SDS-PAGE), His Tag | IL-13 receptor binding and blocking validation | |
Receptor / binding protein | Recombinant Human IL-22BP Protein | Animal Free, Carrier Free, Bioactive, ActiBioPure™, High Performance, ≥95%(SDS-PAGE), See COA, His Tag | IL-22 binding antagonism; Pathway blockade and mechanistic validation | |
Neutralizing Antibody | Tocilizumab anti-IL-6R | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA | IL-6 signaling blockade Mechanism validation | |
Neutralizing Antibody | Sarilumab anti-IL-6R alpha | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA | IL-6R pathway blockade Functional control | |
Neutralizing Antibody | Chugai SK2 anti-IL-6 | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA | IL-6 ligand neutralization Pathway attribution validation | |
Neutralizing Antibody | Secukinumab anti-IL-17A | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA | IL-17A neutralization Th17 axis mechanism validation | |
Neutralizing Antibody | Bimekizumab anti-IL-17A and IL-17F | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA | Dual-target neutralization Th17-related inflammation axis attribution | |
Neutralizing Antibody | Daclizumab anti-IL2RA | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA | Blocking the high-affinity IL-2 receptor T cell expansion axis validation | |
Neutralizing Antibody | Fezakinumab anti-IL-22 | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA | IL-22 neutralization Barrier repair and inflammation studies | |
Neutralizing Antibody | Itepekimab anti-IL-33 | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA | IL-33 neutralization Allergy and mucosal immunity axis validation | |
Neutralizing Antibody | Anrukinzumab anti-IL-13 | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA | IL-13 neutralization Type 2 immune pathway validation | |
Detection Antibody | IL-6 Mouse mAb | ExactAb™, Validated, Carrier Free, Azide Free, High Performance, ≥95%(SDS-PAGE), 0.5 mg/mL | ELISA and detection assays Capture or detection antibody | |
Detection Antibody | IL-10 Mouse mAb | Carrier Free, ExactAb™, Azide Free, Validated, See COA | ELISA and quantitative assays Antibody support | |
Detection Antibody | Recombinant IL-23 Antibody | ExactAb™, Validated, Recombinant, 1.55 mg/mL | IL-23-related detection and functional studies | |
Detection Antibody | IL-10RA Antibody | ExactAb™, Validated, Carrier Free, 0.5 mg/mL | Receptor expression and localization detection | |
Neutralizing antibody | PF-06342674 anti-IL-7R alpha | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA | IL-7Rα pathway blockade; Mechanistic validation |
The interleukin network is a core framework by which the immune system transmits information and regulates effector functions. Its essential features lie in receptor-expression profiles determining response windows, signaling modules determining transcriptional outputs, and network redundancy and negative feedback determining homeostatic boundaries. For basic research, a verifiable mechanistic chain should be constructed along the line of receptor—signaling—functional endpoints, and multi-factor coupled effects should be handled using temporal and combination rules. For biomarker and translational applications, tiered endpoint systems and boundary-clear expression standards should be maintained, with molecular readout changes, cellular functional changes, and clinical phenotype associations stated in layers, and with systematic safety assessments and dynamic monitoring supporting reproducibility and scalability of intervention strategies.
For more related articles, please see below:
[1] Interleukins - the communications arm of the immune response
Aladdin: https://www.aladdinsci.com/